PR in the Philippines

HONG KONG, May 29, 2025 - (ACN Newswire via SeaPRwire.com) – MODONG Coffee, a leading global health and wellness brand, is proud to announce its sponsorship of G-DRAGON 2025 WORLD TOUR [Übermensch] IN TAIPEI, presented by KGI FINANCIAL GROUP, taking place on July 11 (Fri.) and July 13 (Sun.) at the Taipei Arena. As the Official Sponsor, MODONG Coffee brings an innovative fusion of “Music × MODONG Energy” to create an immersive audiovisual experience for fans. This collaboration marks a strategic milestone in MODONG Coffee’s youth-centric expansion, advancing its “IP + Scenarios + New Retail” ecosystem.As one of Asia's most influential music IPs, G-DRAGON’s upcoming tour, themed "Übermensch", symbolizes his groundbreaking interpretation of art and self-expression. As an Official Sponsor, MODONG Coffee joins forces with Samsung, ADATA Technology, and other brands to deliver an immersive experience, seamlessly blending stunning visuals with exceptional music for the audience. As the flagship product of Star Plus Legend's new retail business, MODONG Coffee has established a leading position in China’s bulletproof drink market since its launch in 2019 with its differentiated product positioning. According to China Insights Consultancy, MODONG coffee has ranked first in the bulletproof drink market by GMV in the PRC for five consecutive years (2020-2024). As of 2024, the cumulative sales of MODONG coffee have reached 100 million cups. That same year, MODONG brand and its products earned multiple prestigious certifications, including “a high profile brand in Jiangsu province” and “the iSEE list of top 100 innovative brands”, further solidifying its market competitiveness.Additionally, MODONG Coffee has deeply integrated with the phenomenal variety show IP "J-Style Trip", achieving "traffic-to-sales conversion" through celebrity-driven marketing and scenario-based campaigns. This strategy drove a 360% year-on-year sales surge in its debut year, propelling Star Plus Legend’s net profit to soar 233% YoY. To meet evolving consumer demands, MODONG Coffee underwent a brand upgrade in 2025, launching the MODONG MAGIC series—Sicilian Lemon Coffee and Cactus Black Coffee—under the concept "A Cup On-the-Go: Crafting Magic for Healthy Living". The brand aims to pioneer a new MODONG lifestyle rooted in low-carb diets and scientific fitness, fostering healthier habits and redefining the relationship between nutrition and wellness. To amplify brand influence, MODONG MAGIC became the exclusive title sponsor of "J-Style Trip Season 3". The show has aired nine episodes to date, dominating CSM71-city provincial satellite TV ratings with nine consecutive time-slot No.1 rankings. It generated 298 trending topics and over 2.9 billion impressions across platforms, igniting widespread social engagement. The support for the "G-DRAGON 2025 WORLD TOUR [Übermensch] IN TAIPEI, presented by KGI FINANCIAL GROUP" represents a key step in MODONG Coffee’s strategic layout of combining “healthy trendy beverages + entertainment.” By leveraging G-DRAGON's global fan appeal and the high popularity of the concert, the brand aims to further expand its influence in the Asia-Pacific market — marking a significant leap for MODONG Coffee from product to brand, and from local to global.Looking ahead, MODONG will remain sharply focused on Gen Z consumers, engaging them through health, music, fashion, and digital art to strengthen its youth-oriented identity. Powered by AI-driven IP innovation, the brand is poised to accelerate the fusion of digital technology and the real economy. Copyright 2025 ACN Newswire via SeaPRwire.com.

Key Highlights- Clinical trial to evaluate the safety and efficacy of YK012 in primary membranous nephropathy- Globally, this is the first bispecific CD19-directed CD3 T cell engager immunotherapy for this autoimmune disease- Milder T cell activation than Blincyto and Target cell-dependent T cell activation- Multiple CR cases observed in ongoing r/r NHL Phase Ia trial and r/r ALL Phase Ib/II trialHONG KONG, May 29, 2025 - (ACN Newswire via SeaPRwire.com) – Excyte, a global clinical-stage biotechnology company, announced first patient has been dosed for YK012, the world’s first patient T cell engager that entered into clinical trial for primary membranous nephropathy (pMN). The patient remained well after administration with no adverse reactions witnessed to date.pMN is an autoimmune disease caused by the attack of autoantibodies against podocyte antigens leading to the in situ production of immune complexes. pMN is the most common cause of primary nephrotic syndrome in non-diabetic adults worldwide, accounting for 20% to 37% of affected individuals, and as high as 40% in adults over 60 years of age (1). Currently, 20-30% of pMN cases are resistant to current therapies like rituximab and cyclophosphamide and relapse rates can be high (2).A clear regulatory pathway in this orphan disease in US could make YK012 one of the first approved TCE in the autoimmune space with many other autoimmune and oncology indications to follow. Excyte would file for US investigational new drug (IND) application imminently.The study aims to evaluate the safety, tolerability, and preliminary efficacy of YK012 in PMN patients. Led by Professor Minghui Zhao and Prof Zhao Cui from Peking University First Hospital, the trial is planned to be conducted across multiple centers in China. The clinical trial for this indication in the United States will be collaboratively executed by Excyte and its international partners.“YK012 is a T-cell engaging bispecific antibody targeting both CD19 and CD3, activating T-cell immunity via CD3 while targeting CD19—the most widely expressed tissue-specific marker during B-cell development and thereby enabling B-cell reset. Our data illustrated YK012 mediated significant B cell depletion and have illustrated in current clinical studies extended half-life and limited cytokine release in patients,” said Mr. Andrew Meng, chairman and COO at Excyte. “We look forward to collaborating with regulatory authorities to make YK012 available to this  patient population with a high unmet medical need."In December 2024, YK012 obtained Clinical Trial Approval Notice (No. CXSL2400727) from China's National Medical Products Administration (NMPA) and was registered on ClinicalTrials.gov (NCT06982729). With the first patient dosed in pMN, Excyte now has a global presence in autoimmune diseases in additional to oncology indications such as NHL and ALL. Earlier this year, Excyte also secured clinical trial approval for systemic lupus erythematosus (SLE), with Professor Xiaofeng Zeng from Peking Union Medical College Hospital serving as Principal Investigator.About Excyte Biopharma Ltd.Excyte Ltd. was co-founded by Dr Qing’an Yuan and Mr Andrew Meng , biotech industry veterans with decades of antibody engineering experiences. The company has also established a U.S.-based wholly-owned subsidiary, Excyte LLC, forming a dual-engine drug R&D hub spanning China and the U.S. Excyte is dedicated to developing innovative bispecific antibody drugs for hematologic cancers, multiple myeloma, solid tumors, autoimmune diseases, and other conditions. Excyte’s FIST platform and next generation assets possess features such as long-acting, low-toxicity, and high-yield technological innovations. For more information, please visit https://www.iExcyte.com/Business Development ContactYing Liu, liuying@iExcyte.comReferences:1.William G Couser, Primary Membranous Nephropathy, Clin J Am Soc Nephrol. 2017 May 26;12(6):983–997.2.Elham Ahmadian, Seyed Mahdi Hosseiniyan Khatibi, Sepideh Zununi Vahed, Mohammadreza Ardalan, Novel treatment options in rituximab-resistant membranous nephropathy patients, International Immunopharmacology, Volume 107, 2022, 108635, ISSN 1567-5769. Copyright 2025 ACN Newswire via SeaPRwire.com.

Key Financial Performance Highlights for Q3FY2025:Group’s total revenue for the quarter jumps to RM75.1 million, with e-mobility and energy storage segments as primary contributors, followed by electronicsPerformance for the quarter supported by prompt execution of outstanding orders from FY2024 and progress on new scopes secured within existing client baseBoth PBT and PAT stand at RM3.2 million for the quarter under reviewGP, PBT, PAT, and PATAMI margins recorded at 11.6%, 4.3%, 4.3% and 1.1% respectivelyBANGI, Malaysia, May 29, 2025 - (ACN Newswire via SeaPRwire.com) - Technology leader in providing turnkey, intelligent manufacturing automation solutions, GENETEC TECHNOLOGY BERHAD (“Genetec” or the “Company”), today announced its financial results for the third quarter ended 31 March 2025 (“Q3FY2025”). The Company reported a jump in their revenue to RM75.1 million, on par with the preceding year-on-year revenue levels, supported by the delivery of outstanding and new orders across its core client base. Gross Profit (“GP”) for the quarter came in at RM8.7 million with both profit before tax (“PBT”) and profit after tax (“PAT”) at RM3.2 million, and profit after tax and minority interests (“PATAMI”) at RM0.8 million. GP, PBT, PAT, and PATAMI margins stood at 11.6%, 4.3%, 4.3% and 1.1% respectively.While the Q3FY2025 revenue marked a return to revenue levels previously seen in FY2024, profit margins and PAT for the quarter fell compared with the previous quarter’s PAT of RM6.3 million. The Company noted that this was due to several deliveries in the quarter involving new scopes which involved one-off, non-recurring expenses. Genetec expects margin to normalise in upcoming quarters.Managing Director and Co-founder of Genetec, Chin Kem Weng commented, “Our top-line performance reflects a pickup in project execution and a healthy pipeline on the back of our ongoing client engagement. The margin dip this quarter is temporary, contributed by one-off expenses tied to the new project scopes and are not recurring. As such, we are confident that we will see a recovery in the margins in the coming quarters as project maturity and margin discipline for the new scopes improve. Genetec’s focus remains on deepening our partnerships with clients in key sectors like electric vehicle (“EV”), automotives, and energy storage, while we continue to seek meaningful diversification.”Amid the ongoing shifts in global trade dynamics and supply chain strategies, Genetec sees structural tailwinds supporting its growth trajectory. As manufacturers reassess production footprints and strengthen operational resilience, there is an upward demand for flexible, cost-competitive and reliable high-quality automation solutions. Genetec’s Malaysia-based production model, combined with a proven international track record, deep technical expertise, and agile manufacturing capabilities, positions the Company well to support clients adapting to these changes.The Company remains focused on deepening its engagement with existing customers while exploring opportunities to broaden its client base. In addition to pursuing new scopes within existing clients’ operations, Genetec has actively participated in several international exhibitions and industry events in recent months, which have generated encouraging business leads. These engagements mark early steps toward potential entry into new industries and segments, in line with the Company’s longer-term strategy to diversify and grow.Genetec is also actively managing its current production load while progressing its EPIC plant expansion, scheduled for completion in early 2026. The new facility will significantly increase floor space and technical capabilities, supporting Genetec’s ability to deliver on multiple high-value projects simultaneously.“We remain focused on timely order execution, quality and cost control, and supporting our clients in a rapidly evolving industrial and technological environment. With steady project momentum, a growing base of client engagements, and strategic expansion into new sectors, we are cautiously optimistic about the road ahead. We believe Genetec is well-positioned to build on this foundation for long-term growth,” Chin concluded.With ongoing execution across key client projects and growing interest from new industries, Genetec continues to position itself as a trusted global partner in automation.About Genetec Technology BerhadGenetec Technology Berhad is a public listed company on the Main Market of Bursa Malaysia Securities Berhad (Stock code: 0104) and a global leader in providing customised, turnkey smart factory automation solutions. With a strong international footprint, it serves a diverse range of industries including electric vehicle (EV), e-mobility and energy storage, automotive, hard disk drives (HDD), consumer electronics, appliances, and pharmaceuticals.For more information please visit: https://genetec.net/. Copyright 2025 ACN Newswire via SeaPRwire.com.

WILMINGTON, DE, May 29, 2025 - (ACN Newswire via SeaPRwire.com) - Naoris Protocol, the first quantum-resistant blockchain and cybersecurity mesh architecture, has raised $3 million in a strategic funding round led by Mason Labs, that includes Frekaz Group, Level One Robotics and Tradecraft Capital following a six-month technical due diligence process.The round, which includes proceeds from Naoris’s public sale and related allocations, was oversubscribed, prompting the team to open a new institutional raise — now live as of today, Thursday, 29 May.David Carvalho, CEO and Founder of Naoris Protocol, says: “The strong interest we’ve seen from institutions reflects how urgently the industry is beginning to take the threat of quantum computing seriously. This investment supports our mission to future-proof the blockchain ecosystem before these risks become reality.”Mason Labs, a leading venture capital firm focused on infrastructure-grade technologies, conducted a detailed review of Naoris Protocol’s post-quantum trust structure prior to securing the entire VIP allocation.Rain Huan, Founder of Mason Labs, says: “In recent years, cybersecurity issues related to digital assets have become increasingly severe and a serious challenge also faced by Mason Labs as an institution focusing on on-chain asset trading and investment. Naoris Protocol’s groundbreaking infrastructure layer has the potential to effectively mitigate such security risks. If successful, this would represent a substantial advancement for the Web3 ecosystem.”This latest round follows a $31 million fundraise in 2022 backed by Tim Draper, the Holdun Family Office, Expert Doja, Uniera and other institutional investors.Naoris Protocol is led by a team of cybersecurity, defense, and blockchain leaders, including:David Holtzman, former CTO of IBM and architect of the DNS protocolAhmed Réda Chami, Ambassador for Morocco to the EU and former CEO of Microsoft North AfricaMick Mulvaney, former White House Chief of StaffInge Kampenes, former Major General (ret.) and Chief of Norwegian Armed Forces Cyber DefenceThe protocol offers a plug-and-play cybersecurity mesh designed to protect any blockchain or enterprise system from the sub-zero layer upward, without requiring a hard fork. Its decentralized security layer is powered by post-quantum cryptography and AI, and aligned with standards from NIST, NATO, and ETSI.Naoris Protocol also runs a quantum-resistant Layer 1 blockchain secured by its proprietary Proof-of-Security (dPoSec) consensus mechanism.About Naoris ProtocolNaoris Protocol is the world’s first Decentralized Post-Quantum Infrastructure, built to secure both Web3 and Web2 against traditional and quantum threats. Operating beneath blockchain layers 0 to 3 as a Sub-Zero Layer, it integrates with existing EVM chains, nodes, bridges, dApps, enterprise systems, and IoT devices without requiring hard forks. Naoris Protocol combines Post-Quantum Cryptography, dPoSec Consensus, and Decentralized Swarm AI to create a self-healing security mesh that eliminates single points of failure. Since launching in January 2025, it has processed over 64 million transactions and mitigated 341 million threats. Powered by the $NAORIS token, it is the fastest-growing trust and security layer for a quantum-resilient internet.To learn more about Naoris Protocol, visit https://www.naorisprotocol.com/ Press contact:Anna Fedorovaanna@babslabs.io  Copyright 2025 ACN Newswire via SeaPRwire.com.